Bevacizumab for ophthalmic diseases

References

• Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol. Scand.84, 282–288 (2006).
   PubMedGoogle Scholar
• Wang F, Rendahl KG, Manning WC et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest. Ophthalmol. Vis. Sci.44, 781–790 (2003).
   PubMed Web of Science ®Google Scholar
• Apte RS, Barreiro RA, Duh E et al. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest. Ophthalmol. Vis. Sci.45, 4491–4497 (2004).
   PubMed Web of Science ®Google Scholar
• Kwak N, Okamoto N, Wood JM et al. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci.41, 3158–3164 (2000).
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol.120, 338–346 (2002).
   PubMed Web of Science ®Google Scholar
• Saishin Y, Saishin Y, Takahashi K et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol.195, 241–248 (2003).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351, 2805–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Heier JS, Hantsbarger G et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology113, 632 (2006).
   Web of Science ®Google Scholar
• Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology112, 1048–1053 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Hafiz G et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology113, e1–e14 (2006).
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology112, 1035–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology113, e1–e12 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic. Surg. Lasers Imaging36, 336–339 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging36, 331–335 (2005).
   PubMed Web of Science ®Google Scholar
• Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am. J. Health Syst. Pharm.61, S21–S26 (2004).
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther.288, 371–378 (1999).
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol.19, 843–850 (2001).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.Nature362, 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Brasch R, Pham C, Shames D et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J. Magn. Reson. Imaging7, 68–74 (1997).
   PubMed Web of Science ®Google Scholar
• Ryan AM, Eppler DB, Hagler KE et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol.27, 78–86 (1999).
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Husain D, Theodosiadis P et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch. Ophthalmol.118, 78–84 (2000).
   PubMed Web of Science ®Google Scholar
• Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina26, 262–269 (2006).
   PubMed Web of Science ®Google Scholar
• Schraermeyer UA, Henke-Fahle S, Grisanti S et al. Evidence for transport of bevacizumab through the retina by muller cells in rabbits. ARVO 2006. Abstract 4169 (2006).
   Google Scholar
• Feiner L, Barr EE, Shui YB et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina26, 882–888 (2006).
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Cameron JD, McCannel CA et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am. J. Ophthalmol.142, 162–164 (2006).
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina26, 257–261 (2006).
   PubMed Web of Science ®Google Scholar
• Kiss C, Michels S, Prager F et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina26, 877–881 (2006).
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Warga M, Neuhann IM et al. Does intravitreal injection of bevacizumab have an effect on the blood–aqueus barrier function? Br. J. Ophthalmol.90, 922 (2006).
   PubMedGoogle Scholar
• Luke M, Warga M, Ziemssen F et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br. J. Ophthalmol.90, 1178–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina26, 270–274 (2006).
   PubMed Web of Science ®Google Scholar
• Luthra S, Narayanan R, Marques LE et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina26, 512–518 (2006).
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Wallenfels-Thilo B, Sierra A et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br. J. Ophthalmol.90, 1316–1321 (2006).
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder M, Reid J et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology114(5), 855–859 (2007).
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci.46, 726–733 (2005).
   PubMed Web of Science ®Google Scholar
• Beer PM, Wong SJ, Hammad AM et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina26, 871–876 (2006).
   PubMed Web of Science ®Google Scholar
• Peters S, Julien S, Heiduschka P et al. Anti-permeability and anti-proliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br. J. Ophthalmol. DOI: 109702v1 (2006) (Epub ahead of print).
   Google Scholar
• Bakri SJ, Snyder MR, Pulido JS et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina26, 519–522 (2006).
   PubMed Web of Science ®Google Scholar
• Michels SM, Rosenfeld PJ, Geitzenauer W et al. Standard vs. reduced dose systemic bevacizumab (Avastin®) for the treatment of neovascular age-related macular degeneration. ARVO 2006. Abstract 5231 (2006).
   Google Scholar
• Geitzenauer W, Michels S, Prager F et al. [Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration]. Klin. Monatsbl. Augenheilkd.223, 822–827 (2006).
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah S, Tatlipinar S et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br. J. Ophthalmol.89, 1368–1370 (2005).
   PubMed Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med.354, 980–982 (2006).
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology113, 363–372 (2006).
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina26, 495–511 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina26, 383–390 (2006).
   PubMed Web of Science ®Google Scholar
• Aisenbrey S, Ziemssen F, Volker M et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0471-7 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol.245, 68–73 (2007).
   PubMed Web of Science ®Google Scholar
• Yoganathan P, Deramo VA, Lai JC et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina26, 994–998 (2006).
   PubMed Web of Science ®Google Scholar
• Aggio FB, Farah ME, Silva WC et al. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0412-5 (2006) (Epub ahead of print).
   Google Scholar
• Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch. Clin. Exp. Ophthalmol.245(5), 651–655 (2007).
   PubMed Web of Science ®Google Scholar
• Bashshur ZF, Bazarbachi A, Schakal A et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol.142, 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Costa RA, Jorge R, Calucci D et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest. Ophthalmol. Vis. Sci.47, 4569–4578 (2006).
   PubMed Web of Science ®Google Scholar
• Dhalla MS, Shah GK, Blinder KJ et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina26, 988–993 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging37, 446–454 (2006).
   PubMed Web of Science ®Google Scholar
• Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am. J. Ophthalmol.98, 271–282 (1984).
   PubMed Web of Science ®Google Scholar
• Noma H, Minamoto A, Funatsu H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol.244, 309–315 (2006).
   PubMed Web of Science ®Google Scholar
• Iturralde D, Spaide RF, Meyerle CB et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina26, 279–284 (2006).
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Ziemssen F, Petermeier K et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. Ophthalmologe103(6), 471–475 (2006).
   PubMed Web of Science ®Google Scholar
• Grisanti S, Biester S, Peters S et al. Intracameral bevacizumab for iris rubeosis. Am. J. Ophthalmol.142, 158–160 (2006).
   PubMed Web of Science ®Google Scholar
• Iliev ME, Domig D, Wolf-Schnurrbursch U et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am. J. Ophthalmol.142, 1054–1056 (2006).
   PubMed Web of Science ®Google Scholar
• Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic. Surg. Lasers Imaging37, 144–146 (2006).
   PubMedGoogle Scholar
• Funatsu H, Yamashita H, Nakamura S et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology113, 294–301 (2006).
   PubMed Web of Science ®Google Scholar
• Ogata N, Nishikawa M, Nishimura T et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am. J. Ophthalmol.134, 348–353 (2002).
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye20, 1474–1475 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina26, 275–278 (2006).
   PubMed Web of Science ®Google Scholar
• Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina26, 699–700 (2006).
   PubMedGoogle Scholar
• Oshima Y, Sakaguchi H, Gomi F et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol.142, 155–158 (2006).
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology113, e1–e15 (2006).
   PubMed Web of Science ®Google Scholar
• Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina26, 1006–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina26, 999–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Laud K, Spaide RF, Freund KB et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina26, 960–963 (2006).
   PubMed Web of Science ®Google Scholar
• Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina26, 1093–1094 (2006).
   PubMedGoogle Scholar
• Sakaguchi H, Ikuno Y, Gomi F et al. Intravitreal injection of bevacizumab for choroidal neovascularization caused by pathological myopia. Br. J. Ophthalmol.91(2), 161–165 (2007).
   PubMed Web of Science ®Google Scholar
• Yamamoto I, Rogers AH, Reichel E et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br. J. Ophthalmol.91(2), 157–160 (2007).
   PubMed Web of Science ®Google Scholar
• Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0468-2 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Teixeira A, Moraes N, Farah ME et al. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol. Scand.84, 835–836 (2006).
   PubMedGoogle Scholar
• Siqueira RC, Costa RA, Scott IU et al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol. Scand.84, 834–835 (2006).
   PubMedGoogle Scholar
• Shah PK, Narendran V, Tawansy KA et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J. Ophthalmol.55, 75–76 (2007).
   PubMedGoogle Scholar
• Manzano R, Peyman G, Khan P et al. Inhibition of experimental corneal neovascularization by bevacizumab (AVASTIN). Br. J. Ophthalmol. DOI: 107912v1 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Amselem L, Cervera E, Diaz-Llopis M et al. Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye21(4), 566–567 (2007).
   PubMedGoogle Scholar
• Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina26, 356–357 (2006).
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Deuter CM, Stuebiger N et al. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0512-2 (2007) (Epub ahead of print).
   Google Scholar
• Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin. Drug Saf.5, 289–301 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1432–1444 (2006).
   PubMed Web of Science ®Google Scholar
• D’Amico DJ, Masonson HN, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology113, 992–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol.90, 1344–1349 (2006).
   PubMed Web of Science ®Google Scholar
• Pieramici DJ, Avery RL, Castellarin AA et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina26, 841–842 (2006).
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Patel SP. Retinal pigment epithelial tear following intravitreal bevacizumab. Eye21(3), 424–425 (2007).
   PubMedGoogle Scholar
• Gelisken F, Ziemssen F, Voelker M et al. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol. Scand.84, 833–834 (2006).
   PubMedGoogle Scholar
• Meyer CH, Mennel S, Schmidt JC et al. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br. J. Ophthalmol.90, 1207–1208 (2006).
   PubMed Web of Science ®Google Scholar
• Nicolo M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur. J. Ophthalmol.16, 770–773 (2006).
   PubMedGoogle Scholar
• Shah CP, Hsu J, Garg SJ et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am. J. Ophthalmol.142, 1070–1072 (2006).
   PubMedGoogle Scholar